Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HHK101 in Schizophrenia
NCT07815210Phase 1Not yet recruiting
- Sponsor
- Huahaikang Pharmaceutical
- Start
- Nov 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1 trial of HHK101 in schizophrenia (8 arms), sponsored by Huahaikang Pharmaceutical. Primary endpoints: Adverse Events at 18 weeks, Drug Concentrations at 18 weeks and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
HHK101
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07815210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07815210.